|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Updates |
S Pandya, PT, MS, is Assistant Professor of Neurology and Physical Medicine and Rehabilitation, School of Medicine and Dentistry, University of Rochester, Rochester, NY 14627 (USA)
WM King, PT, BA, is Clinical Assistant Professor of Neurology, Department of Neurology, Ohio State University, Columbus, Ohio
R Tawil, MD, is Professor of Neurology, Department of Neurology, University of Rochester
Address all correspondence to Ms Pandya at: shree_pandya{at}urmc.rochester.edu
Facioscapulohumeral dystrophy (FSHD) is the third most common inherited muscular dystrophy after Duchenne dystrophy and myotonic dystrophy. Over the last decade, major advances have occurred in the understanding of the genetics of this disorder. Despite these advances, the exact mechanisms that lead to atrophy and weakness secondary to the genetic defect are still not understood. The purposes of this article are to increase awareness of FSHD among clinicians; to provide an update regarding the genetics, clinical features, natural history, and current management of FSHD; and to discuss opportunities for research.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
P. Arashiro, I. Eisenberg, A. T. Kho, A. M. P. Cerqueira, M. Canovas, H. C. A. Silva, R. C. M. Pavanello, S. Verjovski-Almeida, L. M. Kunkel, and M. Zatz Transcriptional regulation differs in affected facioscapulohumeral muscular dystrophy patients compared to asymptomatic related carriers PNAS, April 14, 2009; 106(15): 6220 - 6225. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |